Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

January 19, 2021January 19, 2021

UV1 Triple Combo Maintenance Therapy Will Be Tested in Phase 2 Trial

News

Ultimovacs will test its experimental cancer vaccine, UV1, as part of a triple-combination therapy for women with relapsed ovarian cancer who have no mutations in their BRCA DNA repair ... Read more

January 14, 2021January 14, 2021

GPS Vaccine-Keytruda Combo Showing Efficacy in Advanced Cancer Patients

News

Combining the experimental vaccine galinpepimut-S (GPS) with the immune checkpoint inhibitor Keytruda (pembrolizumab) induces promising responses in people with metastatic ovarian cancer who failed one or two prior lines of ... Read more

January 12, 2021January 12, 2021

Lynparza Approved in Japan to Treat Certain Advanced Ovarian Cancers

News

Lynparza (olaparib) has been approved in Japan as a maintenance treatment for women with advanced ovarian cancer who responded to a first-line chemotherapy regimen containing bevacizumab, AstraZeneca and Merck announced in ... Read more

December 22, 2020December 22, 2020

DPX-Survivac Responses Now Up to 16 Months in Advanced Ovarian Cancer Trial

News

IMV‘s immunotherapy DPX-Survivac plus low-dose chemotherapy continues to show sustained benefits in people with heavily treated advanced ovarian cancer, with some benefits lasting up to 16 months, updated findings from ... Read more

October 15, 2020October 15, 2020

First Trial in New NCI-Zenith Partnership Will Test ZEN-3694 Combo for Resistant OC

News

The first clinical trial resulting from a new Zenith Epigenetic collaboration with the National Cancer Institute (NCI) will soon test a combination of the investigational therapy ZEN-3694 plus the ... Read more

September 29, 2020September 29, 2020

STRO-002 Trial Update Supports Its Safety, Activity in Advanced Cancer

News

Updated interim data from a Phase 1 clinical trial continues to support the safety and anti-tumor activity of Sutro Biopharma’s STRO-002 for heavily pre-treated women with advanced ovarian cancer. About one-quarter of patients ... Read more

August 27, 2020August 27, 2020

First Ovarian Cancer Patients Dosed in Phase 2 of OVATION 2 Trial

News

The first two patients have been randomized in Phase 2 of the OVATION 2 trial testing the immunotherapy candidate GEN-1 in newly diagnosed advanced ovarian cancer. Celsion Corporation, the immunotherapy’s developer, ... Read more

June 16, 2020June 16, 2020

DPX-Survivac Shows Durable Responses in Advanced Ovarian Cancers, Trial Data Show

News

A combination of IMV‘s immunotherapy DPX-Survivac plus intermittent low-dose cyclophosphamide leads to sustained responses in women with heavily-treated advanced ovarian cancer, with some responses lasting more than 10 months, ... Read more

June 9, 2020June 9, 2020

More Than Half of Patients Respond to VB-111 Chemo Combo, Trial Data Shows

News

VBL Therapeutic’s investigational therapy VB-111 (ofranergene obadenovec) continues to show promising response rates in women with platinum-resistant ovarian cancer, with more than half of patients enrolled in a Phase ... Read more

April 1, 2020April 1, 2020

Acelarin Trial Shows Potential in Chemo-resistant Ovarian Cancer, But Study Ending

News

Treatment with Acelarin led to one complete response and two partial responses in heavily pre-treated women with platinum-resistant ovarian cancer, early results from a Phase 2 trial show. Full analysis of ... Read more